Form Bio
Austin, US · Founded 2022 · Delaware corporation · 5 known investors
Form Bio develops AI-driven software and bioinformatics tools for genetic medicine and genome engineering, enabling faster and safer design of gene therapies, protein engineering, and manufacturing optimization.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
Form Bio was founded in 2022 by Benjamin Lamm and Andrew Busey.
BL
Benjamin LammCo-founder
AB
Andrew BuseyCo-founder
MC
Michelle Chen, PhD
DD
Doug Daniels
JN
Joe Nipko, PhD
AE
Amicia Elliott, PhD
DK
David Kiger
AA
Angela Anderson
CC
Christina Capehart
KW
Kent WakefordNamed on SEC filing
Board
JS
Investors · 5
Reported raises · per SEC filings
Form D private placements$16M disclosed across 1 round · 2022
▶$16MraisedSep 2022 · 4 investors · BiotechnologyRule 506(b)
▶$16MraisedSep 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SpinaleDirector
- Benjamin LammDirector, Promoter
- Andrew BuseyExecutive Officer, Director, Promoter
- Kent WakefordExecutive Officer, Director, Promoter
- Offering amount
- $26.3M
- Amount sold
- $16M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapGenomeweb31 shared keywordsGenomeWeb's Research Funding section publishes news coverage of research grants and government funding trends in genetics, genomics, and molecular diagnostics. It is an industry news publication serving researchers and organizations in the life sciences.
Formation Bio28 shared keywordsFormation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.
Manifold26 shared keywordsManifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
Bridgebio22 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Companies competing with Form Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Form Bio do?
- Form Bio develops AI-driven software and bioinformatics tools for genetic medicine and genome engineering, enabling faster and safer design of gene therapies, protein engineering, and manufacturing optimization.
- Who founded Form Bio?
- Form Bio was founded by Benjamin Lamm, Andrew Busey in 2022.
- Who are Form Bio's investors?
- Form Bio's investors include Bold Capital Partners, Breyer Capital, Carnrite Ventures, Draper Associates, JAZZ Venture Partners.
- How much funding has Form Bio raised?
- Form Bio has disclosed $16M raised across 1 round.
- Where is Form Bio headquartered?
- Form Bio is headquartered in Austin, US.